biotech · TCR-T Cells · B-ALL · TCRX
TScan Therapeutics
TScan Therapeutics is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker TCRX. Primary therapeutic focus areas include TCR-T Cells, B-ALL, Solid Tumor, Non-Hodgkin Lymphoma, Advanced Sol
Waltham, USA HQ
2018 Founded
152 Employees
Public company Type
TCRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 9
- Drugs
- 5
- Patents
- 0
KXV01 TCR Lentinvivo Injection
Phase 1 · small molecule · Advanced Solid Tumors
KXV01 TCR Lentinvivo Injection for Advanced Solid Tumors is a Phase 1 program (small_molecule) at TScan Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code KXV01-R101-08
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TScan Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Solid Tumors
- Status
- active
- Trials
- 2